SCHEMBL3435448

SCHEMBL3435448

CCC(=O)Oc1csc(N2CCS(=O)(=O)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
LMNA P02545 7/20 0.38
MAPT P10636 4/20 0.38
MAPK1 P28482 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436228 0.82 LMNA (0.37) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL3435738 0.81 HRH3 (0.41) LMNAMAPTMAPK1SMN1; SMN2RAB9A
SCHEMBL3435362 0.80 LMNA (0.35) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL3435414 0.80 SMN1; SMN2 (0.34) LMNAMAPTMAPK1SMN1; SMN2TSHR
SCHEMBL3435733 0.79 DNM1L (0.38) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL3436064 0.75 HRH3 (0.40)
SCHEMBL3435748 0.74 L3MBTL1 (0.56) ALDH1A1SMN1; SMN2KDM4EL3MBTL1HPGD
SCHEMBL3435409 0.73 DNM1L (0.39) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL3550824 0.72 L3MBTL1 (0.47) ALDH1A1LMNAMAPK1SMN1; SMN2MEN1
SCHEMBL27431258 0.72 KMT2A (0.39) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 ALDH1A1 975/4885LMNA 4712/4885MAPT 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.